基于 DNA 超分子水凝胶的保护性 NK 细胞储库用于增强三阴性乳腺癌治疗
Protective NK Cell Reservoir Based on DNA Supramolecular Hydrogel for Enhanced Triple-Negative Breast Cancer Therapy.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
乳腺癌微环境经化疗联合树突状细胞疫苗的修饰：一种选择最佳治疗策略的方法
英文原题：Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies.
查看英文原题
Modification of Breast Cancer Milieu with Chemotherapy plus Dendritic Cell Vaccine: An Approach to Select Best Therapeutic Strategies.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
我们的研究结果表明，TNBC 患者可能通过将 DCV 与 NAC 联合使用，从抗肿瘤免疫系统的刺激中获益。
研究思路结论见上方概要
背景
在NAC基础上加入树突状细胞疫苗（DCV）可通过改变肿瘤微环境，在残留病灶（RD）患者中诱导免疫应答。
方法
选取了80例患者的核心诊断活检和手术标本（38例来自疫苗组加NAC（VG），42例来自对照组（CG，仅接受NAC治疗））。我们使用免疫组织化学和自动细胞成像系统（ACIS III）在配对样本中量化了TILs（CD8、CD4和CD45RO）。
结果
在TNBC样本中观察到NAC加DCV后CD8升高，从活检中的4.48%变为手术标本中的6.70%，未达到统计学显著差异（p = 0.11）。在实验组中，高达67%的TNBC患者出现这种富集，而CG为20%。在单变量和多变量分析中，发现VG中NAC前CD8 TILs（4%截断点）与病理完全缓解之间存在关联（分别为OR = 1.41，IC95% 1.05-1.90；p = 0.02，和OR = 2.0，IC95% 1.05-3.9；p = 0.03）。
展开英文摘要原文
BACKGROUND
The addition of dendritic cell vaccines (DCV) to NAC could induce immune responses in those patients with residual disease (RD) by transforming the tumor microenvironment.
METHODS
Core diagnostic biopsies and surgical specimens from 80 patients (38 in the vaccinated group plus NAC (VG) and 42 in the control group (CG, treated only with NAC) were selected. We quantify TILs (CD8, CD4 and CD45RO) using immunohistochemistry and the automated cellular imaging system (ACIS III) in paired samples.
RESULTS
A CD8 rise in TNBC samples was observed after NAC plus DCV, changing from 4.48% in the biopsy to 6.70% in the surgical specimen, not reaching statistically significant differences ( p = 0.11). This enrichment was seen in up to 67% of TNBC patients in the experimental arm as compared with the CG (20%). An association between CD8 TILs before NAC (4% cut-off point) and pathological complete response in the VG was found in the univariate and multivariate analysis (OR = 1.41, IC95% 1.05-1.90; p = 0.02, and OR = 2.0, IC95% 1.05-3.9; p = 0.03, respectively).
CONCLUSION
Our findings suggest that patients with TNBC could benefit from the stimulation of the antitumor immune system by using DCV together with NAC.
论文信息
- 作者
- Mejías Sosa L、López-Janeiro Á、Córdoba Iturriagagoitia A、Sala P、Solans BP、Hato L、Inogés S、López-Díaz de Cerio A
- 第一作者单位
- Department of Pathology, Hospital Universitario Rey Juan Carlos, Gladiolo, 28933 Madrid, Spain.Spain
- 通讯作者单位
- Department of Medical Oncology, Breast Cancer Unit, Clínica Universidad de Navarra, Pío XII Avenue 36, 31008 Pamplona, Spain.Spain
- 期刊
- Biomedicines2023 Jan 17
- 原文标识
- PubMed 36830775 · DOI 10.3390/biomedicines11020238
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →